Author: Matt Kristoffersen

Extra Shots from J. & J. and Pfizer Give Immune Boost, Companies Report

Posted on by Matt Kristoffersen

The New York Times, August 25, 2021 (with Sharon LaFraniere)

Link

As vaccine makers set their sights on boosters, new studies unveiled on Wednesday from Johnson & Johnson and Pfizer-BioNTech demonstrated that extra shots can dramatically raise antibodies against the coronavirus.

The companies said they were submitting the new data to the Food and Drug Administration for evaluation, and Pfizer has formally asked the agency to authorize a booster shot. The Biden administration said last week that it wants to provide booster shots for all Americans eight months after vaccination.

Continue reading “Extra Shots from J. & J. and Pfizer Give Immune Boost, Companies Report” →

Friday’s Elk, August 13, 2021

Posted on by Matt Kristoffersen

Last month, in an appearance on the Daily podcast, I warned against assuming that the pandemic was over. The Delta variant was poised to potentially sweep across the United States. It might create a surge that might even require that the country return to masking and other measures to slow it down.

I sensed that the Daily host Michael Barbaro did not welcome the news. And I could sympathize. After months of mass vaccination and crashing cases, it was easy to believe that the coronavirus was now behind us. But by early July, there was plenty of evidence that the Delta variant might well push back those gains. It bore mutations allowing it to multiply quickly inside a host and then swiftly spread to new victims. It had already overwhelmed countries like India and the United Kingdom. Vaccines work well against Delta–especially against hospitalization from Covid-19–but only after both doses. Only about half of Americans are fully vaccinated, leaving the rest easy targets for the variant.  Continue reading “Friday’s Elk, August 13, 2021” →

Novavax is still struggling to produce its vaccine

Posted on by Matt Kristoffersen

The New York Times, August 5, 2021

Link

Novavax, the Maryland company that won $1.6 billion from the U.S. government last year to develop a Covid vaccine, on Thursday announced that continued production problems would delay the vaccine’s use in the United States until the end of the year.

But the two-shot vaccine, which performed well against the virus in clinical trials, might soon be used in other parts of the world. In partnership with the Serum Institute of India, Novavax has applied for emergency authorization in India, Indonesia and the Philippines, the company announced on an earnings call.

Continue reading “Novavax is still struggling to produce its vaccine” →

Moderna says its vaccine’s protection holds through six months

Posted on by Matt Kristoffersen

The New York Times, August 5, 2021 (with Sharon LaFraniere)

Link

The powerful protection offered by Moderna’s Covid vaccine does not wane in the first six months after the second dose, according to a statement released by the company on Thursday morning in advance of its earnings call.

But during the call, Moderna executives said they anticipated that boosters would be necessary this fall to contend with the Delta variant, which became common in the United States after the results were collected.

Continue reading “Moderna says its vaccine’s protection holds through six months” →

Those Virus Sequences That Were Suddenly Deleted? They’re Back

Posted on by Matt Kristoffersen

The New York Times, July 30, 2021

Link

A batch of early coronavirus data that went missing for a year has emerged from hiding.

In June, an American scientist discovered that more than 200 genetic sequences from Covid-19 patient samples isolated in China early in the pandemic had puzzlingly been removed from an online database. With some digital sleuthing, Jesse Bloom, a virologist at the Fred Hutchinson Cancer Center in Seattle, managed to track down 13 of the sequences on Google Cloud.

Continue reading “Those Virus Sequences That Were Suddenly Deleted? They’re Back” →